Tandem Diabetes Care Stock Filter Stocks by Fundamentals
| TNDM Stock | USD 19.81 0.15 0.76% |
Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.
Tandem | Shares Owned by Institutions |
Tandem Diabetes ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tandem Diabetes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tandem Diabetes' managers, analysts, and investors.Environmental | Governance | Social |
Tandem Diabetes Institutional Holders
Institutional Holdings refers to the ownership stake in Tandem Diabetes that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tandem Diabetes' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tandem Diabetes' value.| Shares | Champlain Investment Partners, Llc | 2024-12-31 | 1.4 M | Hood River Capital Management Llc | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 1.1 M | Chicago Capital Llc | 2024-12-31 | 970.6 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 950.9 K | Gilder Gagnon Howe & Co Llc | 2024-12-31 | 931.9 K | Brown Advisory Holdings Inc | 2024-12-31 | 913.1 K | Paradice Investment Management Llc | 2024-09-30 | 903.4 K | Two Sigma Advisers, Llc | 2024-12-31 | 881.8 K | Blackrock Inc | 2024-12-31 | 11.7 M | Vanguard Group Inc | 2024-12-31 | 7.4 M |
Tandem Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0645 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 1.34 B | ||||
| Shares Outstanding | 66.47 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 7.08 M | ||||
| Price To Earning | 494.25 X | ||||
| Price To Book | 4.97 X | ||||
| Price To Sales | 1.40 X | ||||
| Revenue | 940.2 M | ||||
| Gross Profit | 489.57 M | ||||
| EBITDA | (99.13 M) | ||||
| Net Income | (96.03 M) | ||||
| Cash And Equivalents | 608.73 M | ||||
| Cash Per Share | 9.47 X | ||||
| Total Debt | 473.56 M | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 4.80 X | ||||
| Book Value Per Share | 3.97 X | ||||
| Cash Flow From Operations | 24.23 M | ||||
| Short Ratio | 2.72 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Target Price | 41.0 | ||||
| Number Of Employees | 2.65 K | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 1.32 B | ||||
| Total Asset | 967.66 M | ||||
| Retained Earnings | (1.05 B) | ||||
| Working Capital | 477.44 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 26.52 M | ||||
| Net Asset | 967.66 M |
About Tandem Diabetes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tandem Diabetes Piotroski F Score and Tandem Diabetes Altman Z Score analysis. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth 0.436 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.